Tamiflu - the wrong message?

The widespread use of oseltamivir (Tamiflu) has been a key strategy in tackling the H1N1 ‘swine flu’ pandemic in the UK. However, there have been growing concerns about the communication of this approach and rationale behind the policy itself. In this podcast Dr Ike Iheanacho, DTB editor, discusses the policy with two members of the DTB editorial board, Dr Paul Caldwell, a general practitioner and Dr Mahdad Noursadeghi, an infectious diseases consultant. This is an extension of our September 2009 Editorial, Tamiflu − the wrong message? DTB 2009; 47: 97.

Om Podcasten

The Drug and Therapeutics Bulletin (DTB) Podcast is your source for practical, independent, and evidence-based information on drugs, medication, and prescribing. Join the Editor-in-Chief and Deputy Editor of DTB each month as they discuss the key highlights of the latest issue. DTB - dtb.bmj.com - is published by BMJ Group, and offers rigorous, independent evaluations and practical advice on treatments and disease management for doctors, pharmacists, and healthcare professionals. Subscribe to the DTB Podcast and get the latest drug and therapeutic insights. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.